These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

Fintel reports that on May 19, 2025, D. Boral Capital downgraded their outlook for Imunon (NasdaqCM:IMNN) from Buy to Hold.

Imunon (IMNN) stock rocketed higher on Friday after the pharmaceutical company announced positive results from its Phase 2 OVATION 2 Study of IMNN-001. This study was focused on using IMNN-001 as a ...

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 shares of common stock or pre-funded warrants at $0.45 each.

On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

IMUNON, Inc. announced promising results from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for advanced ovarian cancer, which demonstrated significant improvements in ...

“As we continue to evaluate findings from our Phase 2 OVATION 2 Study, the data show consistently strong improvement in overall and progression-free survival, suggesting that IMNN-001 may drive ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...

It also underscores the scientific community's strong and historic evidence of IMNN-001 anti-cancer cancer potential. We believe we have much to offer the future of oncology treatment. And I hope ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival ...